Key result
The iWAVE prospective cohort study plans to enroll approximately 10,000 participants in China to assess the disease trajectory, risk factors, and long-term prognosis of valvular heart disease.
Why the study?
Valvular heart disease prevalence is rising in China, where resource-constrained western regions lack an integrated care management system and a comprehensive lifespan cohort data platform.
Cohort (n=10,000)
Yes
The iWAVE study protocol outlines a large-scale prospective cohort to evaluate the disease trajectory, risk factors, and long-term outcomes of valvular heart disease in China.
Answers are grounded in this paper and cite their sources.
Provides foundational VHD cohort platform in western China; leaves open whether integrated care improves screening, progression, or post-surgical outcomes.
INTRODUCTION: Despite the rapid advancements in cardiovascular surgery in China, the prevalence of valvular heart disease (VHD) continues to rise, particularly among the elderly population. In the resource-constrained western regions, the lack of an integrated care management system significantly contributes to the burden of cardiovascular disease. Consequently, a comprehensive cohort data platform that encompasses the entire lifespan of patients with VHD is essential. This prospective cohort study aims to facilitate the examination of risk factor screening, disease progression, diagnostic and treatment strategies, and the long-term functional recovery trajectories of patients following valve surgery. METHODS AND ANALYSIS: The Integrated Whole-Life Cycle Accuracy Valvular Heart Disease Epidemiology Cohort Study is a prospective cohort study that plans to enrol approximately 10 000 participants, including both patients with VHD and members of the general population, by 2028. Led by the West China Hospital of Sichuan University, it will be conducted in collaboration with 15 medical consortiums and their affiliated community hospitals. This study seeks to assess the disease trajectory of VHD, as well as the risk factors and protective measures that influence its progression and prognosis. This study will collect and analyse basic demographic information, peripheral blood and tissue samples, long-term functional follow-up data, and patient-reported outcome questionnaires. Additionally, electronic health records will be used to document patients with VHD undergoing surgical interventions, along with lifetime endpoint events for the valve clinical study. ETHICS AND DISSEMINATION: The study protocol was approved by the Biomedical Research Ethics Committee of West China Hospital of Sichuan University (No. 20232422). All participants will be required to provide written informed consent. The study findings will be disseminated via publications in peer-reviewed journals and presentations at scientific conferences.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2024) conducted a cohort in Valvular heart disease (n=10,000). Valvular heart disease risk factors and protective measures was evaluated on Disease trajectory, progression, and prognosis of valvular heart disease. The iWAVE prospective cohort study plans to enroll approximately 10,000 participants in China to assess the disease trajectory, risk factors, and long-term prognosis of valvular heart disease.
Synapse has enriched 10 related papers. Consider them for comparative context: